Literature DB >> 22934946

Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays.

Francisco J Diaz1, Peter R McDonald, Anuradha Roy, Byron Taylor, Ashleigh Price, Jessica Hall, Brian S J Blagg, Rathnam Chaguturu.   

Abstract

The half maximal inhibitory concentration (IC₅₀) has several limitations that make it unsuitable for examining a large number of compounds in cytotoxicity studies, particularly when multiple exposure periods are tested. This article proposes a new approach to measure drug effectiveness, which allows ranking compounds according to their toxic effects on live cells. This effectiveness measure, which combines all exposure times tested, compares the growth rates of a particular cell line in the presence of the compound with its growth rate in the presence of DMSO alone. Our approach allows measuring a wider spectrum of toxicity than the IC₅₀ approach, and allows automatic analyses of a large number of compounds. It can be easily implemented in linear regression software, provides a comparable measure of effectiveness for each investigated compound (both toxic and non-toxic), and allows statistically testing the null hypothesis that a compound is non-toxic versus the alternative that it is toxic. Importantly, our approach allows defining an automated decision rule for deciding whether a compound is significantly toxic. As an illustration, we describe the results of a cellbased study of the cytotoxicity of 24 analogs of novobiocin, a C-terminal inhibitor of heat shock protein 90 (Hsp90); the compounds were ranked in order of cytotoxicity to a panel of 18 cancer cell lines and 1 normal cell line. Our approach may also be a good alternative to computing the half maximal effective concentration (EC₅₀) in studies searching for compounds that promote cell growth.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22934946      PMCID: PMC3655799          DOI: 10.2174/1386207311316030002

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  14 in total

1.  Hsp90 inhibitors identified from a library of novobiocin analogues.

Authors:  Xiao Ming Yu; Gang Shen; Len Neckers; Helen Blake; Jeff Holzbeierlein; Benjamin Cronk; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2005-09-21       Impact factor: 15.419

Review 2.  Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.

Authors:  Wanping Xu; Len Neckers
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

3.  The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines.

Authors:  G Malich; B Markovic; C Winder
Journal:  Toxicology       Date:  1997-12-31       Impact factor: 4.221

4.  Design and analysis of in vitro antitumor pharmacodynamic studies.

Authors:  J E Kalns; N J Millenbaugh; M G Wientjes; J L Au
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

Review 5.  Hsp90: a drug target?

Authors:  Jeffrey M Holzbeierlein; Andrew Windsperger; George Vielhauer
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

6.  Effects of respiratory mechanical forces on the pharmacological response of lung cancer cells to chemotherapeutic agents.

Authors:  Peter Hendricks; Francisco J Diaz; Sarah Schmitt; G Sitta Sittampalam; Victor Sanjit Nirmalanandhan
Journal:  Fundam Clin Pharmacol       Date:  2011-07-01       Impact factor: 2.748

Review 7.  Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.

Authors:  Chrisostomos Prodromou
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 8.  Update on Hsp90 inhibitors in clinical trial.

Authors:  Y S Kim; S V Alarcon; S Lee; M-J Lee; G Giaccone; L Neckers; J B Trepel
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

9.  The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity.

Authors:  Alison C Donnelly; Jared R Mays; Joseph A Burlison; John T Nelson; George Vielhauer; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  J Org Chem       Date:  2008-10-22       Impact factor: 4.354

10.  KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.

Authors:  Shary N Shelton; Mary E Shawgo; Shawna B Matthews; Yuanming Lu; Alison C Donnelly; Kristen Szabla; Mehmet Tanol; George A Vielhauer; Roger A Rajewski; Robert L Matts; Brian S J Blagg; John D Robertson
Journal:  Mol Pharmacol       Date:  2009-09-09       Impact factor: 4.436

View more
  3 in total

1.  The University of Kansas High-Throughput Screening laboratory. Part I: meeting drug-discovery needs in the heartland of America with entrepreneurial flair.

Authors:  Peter R McDonald; Anuradha Roy; Rathnam Chaguturu
Journal:  Future Med Chem       Date:  2011-05       Impact factor: 3.808

2.  Measuring and Statistically Testing the Size of the Effect of a Chemical Compound on a Continuous In-Vitro Pharmacological Response Through a New Statistical Model of Response Detection Limit.

Authors:  Francisco J Diaz; Peter R McDonald; Abraham Pinter; Rathnam Chaguturu
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

3.  Eco-toxicological effect of a commercial dye Rhodamine B on freshwater microalgae Chlorella vulgaris.

Authors:  Shanmugam Sudarshan; Vidya Shree Bharti; Sekar Harikrishnan; Satya Prakash Shukla; Govindarajan RathiBhuvaneswari
Journal:  Arch Microbiol       Date:  2022-10-02       Impact factor: 2.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.